Custom Solutions for Obese Beagle Dog Model Development
Download
Obese animal models serve as critical translational bridges in metabolic disorder research, enabling researchers to investigate the complex pathophysiological mechanisms of human obesity and evaluate novel therapeutic interventions. Large animal models, particularly dogs, closely mirror human organ physiology, metabolic pathways, and body scale, making them indispensably superior to conventional rodent models for translational drug validation and device testing.
As a leading preclinical research service provider, Protheragen offers comprehensive, tailored solutions spanning diagnostic development, therapeutic development, disease model development, and preclinical research services. We provide high-fidelity, customized obese Beagle dog models to accelerate anti-obesity drug discovery, pharmacodynamic evaluation, metabolic device testing, and translational research programs.
Overview of Obese Beagle Dog Models
The obese Beagle dog model is a highly translational large-animal model that recapitulates clinically relevant features of metabolic dysfunction, such as significant fat accumulation, dyslipidemia, adipocyte hypertrophy, and systemic metabolic remodeling. Utilizing a prolonged high-fat diet (HFD) combined with sedentary housing, this model effectively mimics human diet-induced obesity (DIO). Compared with rodent models, Beagle dogs share greater genetic, physiological, and metabolic similarities with humans, and their suitable body size allows for serial blood sampling, continuous metabolic monitoring, bio-imaging, and surgical manipulations. Furthermore, their docile temperament ensures high feasibility and reproducibility in long-term preclinical studies.
Applications of Obese Beagle Dog Models
Obese Beagle dog models are versatile preclinical tools widely utilized across drug discovery, device development, and surgical innovation. Key application scenarios include:
Anti-Obesity Pharmacodynamic (PD) Studies
Evaluating the efficacy of weight-loss candidates, gut hormone receptor agonists ( e.g., GLP-1, GIP, and glucagon receptor co-agonists), and small molecules by profiling body weight dynamics, food intake, body condition scores (BCS), and lipid homeostasis.
Metabolic Monitoring & Medical Device Testing
Assessing continuous glucose monitoring (CGM) systems, wearable sensors, and implantable therapeutic devices owing to the dogs' appropriate anatomical scale and physiological tolerance.
Bariatric Surgery & Invasive Procedures
Serving as a suitable surgical model to evaluate the feasibility, gastrointestinal tolerance, anatomical adaptations, and long-term metabolic outcomes of bariatric surgical procedures.
Nutritional & Nutraceutical Interventions
Determining the physiological impacts of novel dietary formulations, functional ingredients, and nutraceuticals on lipid metabolism, systemic inflammation, and energy expenditure.
Workflow for Obese Beagle Dog Model Development
Protheragen executes a rigorous, standardized high-fat diet (HFD) induction workflow to ensure consistent obesity induction and robust model validation:
- Protocol Design & Animal Screening (Weeks -2 to 0): Animal selection, baseline health examination, physical assessment, and group randomization.
- HFD Induction & Monitoring (Weeks 0 to 24): Administration of a calorie-dense high-fat diet (e.g., ~4,832 kcal/kg) along with daily food intake logging and weekly body weight tracking.
- Interim Evaluations (Every 4 Weeks): Periodic assessment of body weight, BCS, fasting blood glucose, and serum lipid profiling.
- Final Model Validation (Week 24): End-point profiling including DEXA/MRI fat fraction scans, serum lipid panels, insulin resistance indices, and histopathological analysis.
Integrated Preclinical Research Services for Obesity
Beyond disease model development, Protheragen delivers one-stop, end-to-end preclinical research services to support the full life cycle of obesity R&D pipelines:
Providing biomarker profiling, multi-omics analysis, karyotype analysis, and AI-assisted data analytics to discover novel metabolic diagnostics, identify translational disease signatures, and optimize patient stratification strategies.
Supporting target identification and validation, drug discovery and optimization, and comprehensive in vitro and in vivo efficacy evaluations using advanced assay platforms tailored to specific drug modalities.
Offering diverse in vitro cell-based assays, organoid platforms, and custom in vivo animal models across multiple species to precisely recapitulate complex human metabolic and physiological disease phenotypes.
Delivering full-profile PK /PD modeling, systemic safety assessment, bioanalysis, and toxicology studies across large and small animal species to build robust IND-enabling regulatory data packages.
Case Study-Obese Beagle Dog Model
In this study, an obese Beagle dog model was successfully established using a prolonged high-fat diet (HFD, 4,832 kcal/kg) induction protocol over 24 weeks alongside a normal chow control group (NC, 3,615 kcal/kg). Physical examination and longitudinal monitoring demonstrated that 24 weeks of HFD feeding led to significant, progressive increases in body weight, body weight gain percentage, and body condition scores (BCS) compared with the control group. These findings confirmed the reliable recapitulation of diet-induced obesity, establishing a robust baseline for phenotypic evaluation.
Fig 1. (A) Body weight, (B) body weight gain percentage, and (C) body condition scoring (BCS) of Beagle dogs in the normal chow (NC) group and high-fat diet (HFD) group at baseline (0 weeks) and endpoint (24 weeks). Data are presented as mean ± SEM (n = 8 beagles/group). ** P < 0.01, *** P < 0.001 vs. NC group.
Further structural and systemic characterization fully validated the metabolic disease phenotype of the model. Non-invasive MRI fat-fraction mapping and H&E tissue staining revealed marked expansion of total adipose tissue (TAT)—encompassing both visceral and subcutaneous fat depots—along with distinct adipocyte hypertrophy. Additionally, hematological and lipid profiling demonstrated significant metabolic dysregulation, highlighted by markedly elevated plasma total cholesterol (TC) and low-density lipoprotein (LDL-C) levels. Together, these complementary endpoints validate the model as a highly translational, clinically relevant platform for anti-obesity drug discovery and metabolic therapeutic assessment.
Fig 2. Evaluation of serum lipid profiles in the NC and HFD groups at 24 weeks. (A) Total cholesterol (TC), (B) triglycerides (TG), and (C) low-density lipoprotein cholesterol (LDL-C). Data are expressed as mean ± SEM (n = 8 beagles/group). ** P < 0.01, *** P < 0.001 vs. NC group.
Why Choose Us?
- Scientific Expertise: Driven by a multidisciplinary team of veteran researchers whose deep technical insights ensure scientific rigor and study success.
- Integrated Services: Delivering seamless end-to-end support from custom model development to complex in vivo pharmacodynamic testing.
- Innovative Platforms: Utilizing state-of-the-art technologies, including advanced imaging (MRI/PET/SPECT/CT), histological analysis, and genetic engineering.
- Customized Solutions: Providing bespoke study designs tailored precisely to the specific pharmacological profiles and strategic goals of client pipelines.
Contact Us
Leveraged by state-of-the-art facilities and deep translational expertise, Protheragen delivers reliable obese Beagle dog models and integrated preclinical testing pipelines to advance your metabolic candidates. Our robust study execution and high-quality data packages enable rapid, confident decision-making throughout every stage of your research. Partner with us to de-risk your obesity pipeline and streamline your drug discovery process. Contact our scientific team today to discuss your customized study design.
Resource Download Request
Please complete the form to download the requested resources.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.